Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Bayesian multivariate linear mixed-effects models with varied association structures.

Statistical methods in medical research·2026

Same author

Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations.

European journal of neurology·2026

Same author

Quantitative Muscle MRI of the Lower Extremities Reveals Different Patterns of Involvement in Classic Infantile and Young Late-Onset Pompe Patients.

Journal of inherited metabolic disease·2026

Same author

Unfavorable cardiovascular risk profile without increased event prevalence in late-onset Pompe disease: an individually matched cohort study.

Orphanet journal of rare diseases·2026

Same author

Population Pharmacokinetic/Pharmacodynamic Modeling of Therapeutic Enzymes in Lysosomal Storage Diseases.

Clinical pharmacokinetics·2026

Same author

Antibody formation and efficacy of enzyme replacement therapy in adults with Pompe disease: Unlocking long-term insights.

Genetics in medicine : official journal of the American College of Medical Genetics·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026

Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026

查看所有相关文章

Search research articles

相关实验视频

Updated: Jun 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

这是庞培病.

Ans T van der Ploeg¹, Arnold J J Reuser

¹Department of Paediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC, Sophia Children's Hospital, University Medical Centre, Rotterdam, The Netherlands. a.vanderploeg@erasmusmc.nl

Lancet (London, England)

|October 22, 2008

概括

此摘要是机器生成的。

庞培病是一种罕见的遗传性疾病,导致溶酶体内糖原的积累. 酶替代疗法显著改善了这种渐进的代谢和肌肉疾病的治疗选择.

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Published on: July 15, 2014

相关实验视频

Last Updated: Jun 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Published on: July 15, 2014

科学领域:

生物化学生物化学
遗传学是一个遗传学.
儿科儿科儿科

背景情况:

庞培病,也称为二型糖原储存疾病或酸马尔塔酶缺乏症,是一种泛种族的自体递归代谢障碍.
它的特点是酶酸α-葡萄糖酶的缺乏,导致溶酶体内糖原的积累.
这种普遍的糖原储存会影响多个器官系统,主要影响肌肉功能,导致渐进的移动性和呼吸系统问题.

研究的目的:

提供庞培病的全面概述,包括其病理生理学,临床谱和诊断方法.
突出患者护理的重大进展,特别是酶替代疗法 (ERT) 的开发和批准.
讨论关于疾病机制和新兴治疗策略的最新见解.

主要方法:

对佩病现有文献的审查,包括遗传学,生化学和临床研究.
分析酶替代疗法 (α-糖酶) 的历史发展和监管批准.
讨论目前的临床实践和庞培病管理的未来方向.

主要成果:

庞培病具有广泛的临床谱,从婴儿期到成年期都会影响个体,心脏缩是婴儿形式的标志.
2006年批准的用糖酶α的酶替代疗法 (ERT) 的出现改变了治疗领域,提供了一种减轻疾病进展的手段.
这种治疗进步将庞培病置于可用治疗方法的越来越多的溶酶体储存障碍中.

结论:

酶替代疗法代表了管理庞培病的重大突破,显著改善了患者的治疗结果.
对疾病病理生理学和治疗干预措施的持续研究对于进一步提高对庞培病患者的护理至关重要.
提高认识和传播最新的诊断和管理知识对于优化患者护理和结果至关重要.